Buy Aurobindo Pharma, target price Rs 564: BNP Paribas Securities

Buy Aurobindo Pharma, target price Rs 564: BNP Paribas Securities
ETMarkets.com
Rate Story
Share
Font Size
Save
Comment
Synopsis

Promoters held 51.83 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.43 per cent, DIIs 16.55 per cent.

BuyAgencies
Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 25678.76 Crore) operating in Pharmaceuticals sector.
Securities has buy call on with a target price of Rs 564.The current market price of Aurobindo Pharma is Rs 433.4.

Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 25678.76 Crore) operating in Pharmaceuticals sector.

Aurobindo Pharma key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2022.

Financials
For the quarter ended 30-09-2022, the company has reported a Consolidated Total Income of Rs 5796.56 Crore, down -7.65 % from last quarter Total Income of Rs 6276.54 Crore and down -4.01 % from last year same quarter Total Income of Rs 6038.50 Crore. Company has reported net profit after tax of Rs 411.60 Crore in latest quarter.

The company’s top management includes Mr.K Ragunathan, Mr.K Nithyananda Reddy, Mr.P Sarath Chandra Reddy, Dr.M Sivakumaran, Mr.M Madan Mohan Reddy, Mr.P V Ramprasad Reddy, Mrs.Savita Mahajan, Mr.Girish P Vanvari, Dr.(Mrs.)Avnit Bimal Singh. Company has BSR & Associates LLP as its auditors. As on 30-09-2022, the company has a total of 59 Crore shares outstanding.

Promoter/FII Holdings
Promoters held 51.83 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.43 per cent, DIIs 16.55 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on Aurobindo Pharma Ltd.. Explore Now